BidaskClub Lowers Catalyst Pharmaceuticals (NASDAQ:CPRX) to Buy

BidaskClub cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a strong-buy rating to a buy rating in a report released on Thursday, BidAskClub reports.

Several other research analysts have also weighed in on CPRX. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $5.75 target price on the stock in a report on Wednesday, July 31st. HC Wainwright reiterated a buy rating and set a $9.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, October 31st. SunTrust Banks reiterated a buy rating and set a $11.00 target price (up from $9.00) on shares of Catalyst Pharmaceuticals in a report on Thursday, August 8th. Cantor Fitzgerald lifted their target price on Catalyst Pharmaceuticals from $10.00 to $12.00 in a report on Thursday, August 8th. Finally, ValuEngine lowered Catalyst Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Catalyst Pharmaceuticals has a consensus rating of Buy and a consensus target price of $8.46.

Shares of Catalyst Pharmaceuticals stock traded up $0.10 during trading on Thursday, reaching $4.54. 1,859,500 shares of the company were exchanged, compared to its average volume of 2,036,880. The company has a quick ratio of 5.07, a current ratio of 5.04 and a debt-to-equity ratio of 0.01. Catalyst Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $7.67. The business has a 50-day moving average price of $4.99 and a 200-day moving average price of $4.77. The firm has a market capitalization of $484.32 million, a price-to-earnings ratio of -13.76 and a beta of 2.37.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Catalyst Pharmaceuticals had a return on equity of 15.53% and a net margin of 12.99%. The business had revenue of $30.90 million during the quarter, compared to analysts’ expectations of $33.19 million. On average, equities research analysts forecast that Catalyst Pharmaceuticals will post 0.37 EPS for the current fiscal year.

In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany bought 10,000 shares of Catalyst Pharmaceuticals stock in a transaction on Thursday, October 3rd. The shares were purchased at an average cost of $4.89 per share, for a total transaction of $48,900.00. Following the completion of the acquisition, the chief executive officer now owns 4,772,693 shares in the company, valued at approximately $23,338,468.77. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 10.70% of the company’s stock.

Institutional investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the second quarter valued at about $293,000. JPMorgan Chase & Co. lifted its holdings in shares of Catalyst Pharmaceuticals by 2.0% in the second quarter. JPMorgan Chase & Co. now owns 956,946 shares of the biopharmaceutical company’s stock valued at $3,569,000 after purchasing an additional 18,470 shares in the last quarter. Gables Capital Management Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 0.9% in the third quarter. Gables Capital Management Inc. now owns 490,564 shares of the biopharmaceutical company’s stock valued at $2,606,000 after purchasing an additional 4,500 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Catalyst Pharmaceuticals in the second quarter valued at about $101,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,861,728 shares of the biopharmaceutical company’s stock valued at $18,669,000 after purchasing an additional 95,933 shares in the last quarter. Institutional investors own 63.91% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Article: Why are gap-down stocks important?

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.